BioMedomics Inc

Founded in 2007, BioMedomics is a privately-held clinical diagnostics company in North Carolina, USA. Their researchers combine biology, biochemistry and biomedical engineering to merge advanced technologies with novel point-of-care diagnostic platforms.

Sickle cell disease (SCD) is an inherited blood disorder which often causes red blood cells to become sickle shaped through the presence of the abnormal haemoglobin S variant. Highly rigid sickle-shaped blood cells may have difficulty in passing though small blood vessels, blocking the normal blood flow, damaging tissues and leading to many complications of SCD. Additionally, red blood cells containing mostly haemoglobin S only survive for approximately 16 days compared to 120 days for normal red blood cells. Early diagnosis is key to initiate life-saving therapies.

BioMedomics Sickle SCAN® is the world’s first rapid, point-of-care test for sickle cell disease and trait. The test delivers quality results in less than 5 minutes without the need for external equipment, power source of trained laboratory scientists. The new Sickle SCAN EC95 Positive control kit allows on site validation of Sickle SCAN efficacy and quality.